{"schema_version":"secwatch.filing_event.v1","accession":"0001023024-24-000083","form_type":"8-K","ticker":"ANIP","cik":"0001023024","company_name":"ANI PHARMACEUTICALS INC","filed_at":"2024-08-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.918730+00:00","generated_at":"2026-05-31T12:04:38.921433+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"ANI Pharma Q2 record revenues $138M (+18% YoY); raises FY guidance","bullets":["Record Q2 net revenues $138.0M (+18.4% YoY); Rare Disease Cortrophin Gel $49.2M (+102.4% YoY).","GAAP net loss $(2.7)M ($(0.14)/share); adjusted non-GAAP diluted EPS $1.02; adjusted EBITDA $33.2M.","Raised FY 2024 guidance: rev $540M-$560M, adj. EBITDA $140M-$150M, adj. EPS $4.38-$4.82.","On track to acquire Alimera Sciences (~$5.50/sh cash + CVR) in Q3 2024, adding ILUVIEN and YUTIQ."],"urls":{"canonical":"https://secwatch.observer/filing/0001023024-24-000083","json":"https://secwatch.observer/filing/0001023024-24-000083.json","markdown":"https://secwatch.observer/filing/0001023024-24-000083.md","text":"https://secwatch.observer/filing/0001023024-24-000083.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/0001023024-24-000083-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1023024/000102302424000083/ani-20240806.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T12:04:38.921433+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}